Technetium-99m-ethylenedicysteine has recently been developed for renal function studies. The pharmacokinetics of 99mTc-EC were studied by constant infusion technique and compared with 99mTc-MAG3 and 131I-OIH in 11 patients with various renal disorders. Methods: After giving a 7.4 MBq 131I-OIH and 90-110 MBq 99mTc-EC or 99mTc-MAG3 bolus, a constant infusion (1MBq/ml 99mTc-agent and 0.07 MBq/m 131I-OIH was started. Sixteen blood and five urine samples were obtained over three hr. Results: The renal clearance of 99mTc-EC was higher than that of 99mTc-MAG3. The 99mTc-EC/OIH and 99mTC-MAG3/OIH ratios were 0.75 ± 0.05 and 0.55 ± 0.10 (p = 0.00087), respectively. The distribution volume of 99mTc-EC was also higher than that of 99mTc-MAG3 (15722 ± 4644 and 9509 ± 2788 ml/1.73m2, respectively; p = 0.072). The 99mTc-EC/OIH and 99mTc- MAG3/OIH distribution volume ratios were 1.03 ± 0.14 and 0.55 ± 0.10, respectively (p = 0.0003). The 60-min excretion values of 99mTc-EC and 99mTc-MAG3 were compared to that of OIH. The 99mTc-EC/OIH and 99mTc- MAG3/OIH excretion ratios were 0.96 ± 0.06 and 1.07 ± 0.10, respectively (p = 0.162). The protein binding of 99mTc-EC and OIH were found to be 34% ± 4 and 66% ± 5, respectively (p < 0.0001). The red cell binding of 99mTC- EC was negligible (3% ± 1.2) in comparison to OIH (27% ± 3; p < 0.0001). Conclusion: This limited study demonstrates the pharmacokinetic and renal clearance properties of 99mTc-EC. This agent has good potential for renal function evaluation.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Nuclear Medicine|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging